<DOC>
	<DOCNO>NCT01045707</DOCNO>
	<brief_summary>This trial conduct Asia , Europe United States America ( USA ) . The aim trial compare efficacy safety NN5401 ( insulin degludec/insulin aspart ( IDegAsp ) ) insulin glargine ( IGlar ) , add-on subject 's ongoing treatment metformin + least one OAD ( oral anti-diabetic drug ) . The main period register internally Novo Nordisk NN5401-3590 extension period register NN5401-3726 .</brief_summary>
	<brief_title>Comparison NN5401 Versus Insulin Glargine , Both Combined With Metformin Treatment , Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>For MAIN period ( NN54013590 ) : Diagnosis type 2 diabetes mellitus least 6 month Insulin na√Øve subject Treatment metformin least one oral antidiabetic drug least 3 month trial start Glycosylated haemoglobin ( HbA1c ) 7.5 11.0 % ( inclusive ) Body Mass Index ( BMI ) high 40.0 kg/m^2 For EXTENSION period ( NN54013726 ) : Informed consent obtain trialrelated activity Must complete 26week treatment period ( visit 28 ) trial NN54013590 For MAIN period ( NN54013590 ) : Treatment glucagon like peptide1 ( GLP1 ) receptor agonist and/or thiazolidinedione ( ) within last 3 month prior trial start Cardiovascular disease diagnose within 6 month trial start For EXTENSION period ( NN54013726 ) : Anticipated change concomitant medication know interfere significantly glucose metabolism , systemic corticosteroid , betablockers , Monoamine oxidase ( MAO ) inhibitor Anticipated significant lifestyle change trial , e.g . shift work ( include permanent night/evening shift worker ) , well highly variable eat habit judge physician ) Pregnancy , breastfeeding , intention become pregnant use adequate contraceptive measure accord local requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>